摘要
目的:观察沙库巴曲缬沙坦钠片治疗慢性心力衰竭患者的效果。方法:回顾性分析2022年4月至2024年4月该院收治的260例慢性心力衰竭患者的临床资料,按治疗方案不同分为观察组和对照组各130例。对照组采用常规西药(马来酸依那普利片、呋塞米片、琥珀酸美托洛尔缓释片、螺内酯片、达格列净片、地高辛片)治疗,观察组采用沙库巴曲缬沙坦钠片联合呋塞米片、琥珀酸美托洛尔缓释片、螺内酯片、达格列净片、地高辛片治疗。比较两组临床疗效、血清炎性因子[C反应蛋白(CRP)和降钙素原]水平、左心室射血分数(LVEF)、B型利钠肽(BNP)水平和不良反应发生率。结果:观察组治疗总有效率为96.15%,明显高于对照组的87.69%,差异有统计学意义(P<0.05);治疗后,两组LVEF水平高于治疗前,且观察组高于对照组,两组BNP、CRP、降钙素原水平低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦钠片联合呋塞米片、琥珀酸美托洛尔缓释片、螺内酯片、达格列净片、地高辛片治疗慢性心力衰竭患者可提高其治疗总有效率、LVEF水平,降低其CRP、降钙素原、BNP水平,效果优于马来酸依那普利片联合呋塞米片、琥珀酸美托洛尔缓释片、螺内酯片、达格列净片、地高辛片治疗。
Objective:To observe application effects of Sacubitril Valsartan sodium tablets in treatment of patients with chronic heart failure.Methods:The clinical data of 260 patients with chronic heart failure admitted to this hospital from April 2022 to April 2024 were retrospectively analyzed.According to different treatment options,they were divided into observation group and control group,130 cases in each group.The control group was treated with conventional Western medicine(Enalapril maleate tablets,Furosemide tablets,Metoprolol succinate sustained-release tablets,Spironolactone tablets,Dapagliflozin tablets,and Digoxin tablets),while the observation group was treated with Sacubitril Valsartan sodium tablets combined with Furosemide tablets,Metoprolol succinate sustained-release tablets,Spironolactone tablets,Dapagliflozin tablets,and Digoxin tablets.The clinical efficacy,the levels of serum inflammatory factors [C-reactive protein(CRP) and procalcitonin],left ventricular ejection fraction(LVEF)and brain natriuretic peptide(BNP),and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 96.15%,which was significantly higher than 87.69% of the control group,and the difference was statistically significant(P<0.05).After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of BNP,CRP and procalcitonin in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Sacubitril Valsartan sodium Tablets combined with Furosemide tablets,Metoprolol succinate sustained-release tablets,Spironolactone tablets,Dapagliflozin tablets and Digoxin tablets can improve the total effective rate and the LVEF levels,and reduce the levels of CRP,procalcitonin and BNP in the patients with chronic heart failure.Moreover,it is superior to Enalapril maleate tablets combined with Furosemide tablets,Metoprolol succinate sustained-release tablets,Spironolactone tablets,Dapagliflozin tablets and Digoxin tablets.
作者
李莉
邹子恒
LI Li;ZOU Ziheng(Department of Cardiology of Wuchuan County People’s Hospital,Zunyi 564300 Guizhou,China)
出处
《中国民康医学》
2025年第5期28-30,共3页
Medical Journal of Chinese People’s Health
关键词
慢性心力衰竭
沙库巴曲缬沙坦钠
马来酸依那普利
左心室射血分数
脑利尿钠肽
不良反应
Chronic heart failure
Sacubitril Valsartan sodium
Enalapril maleate
Left ventricular ejection fraction
Brain natriuretic peptide
Adverse reaction
作者简介
李莉(1982.07-),女,汉族,重庆江津人,本科,副主任医师,研究方向为心血管内科疾病诊治。
